Search
Galecto Inc
GLTOAdd to Watchlist
28.690USD
0.0000.00%
Close 07/01, 16:00（ET）Quotes delayed by 15 min
28.21MMarket Cap
LossP/E TTM
More Details of Galecto Inc Company
Galecto, Inc. is a clinical-stage biotechnology company focused on the development of novel treatments for cancer and liver diseases. The Company’s pipeline consists of small molecule drug candidates that target cancer and fibrosis signaling pathways, including a preclinical dual inhibitor of ENL-YEATS and FLT3 (GB3226) for multiple genetic subsets of AML; an orally active galectin-3 inhibitor (GB1211) in combination with a checkpoint inhibitor for various oncology indications and (an orally active galectin-3 inhibitor (GB1211) for the treatment of liver cirrhosis. It is developing GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 for multiple molecularly defined subsets of acute myeloid leukemia (AML). The Company’s pipeline is GB1211, its oral small molecule galectin-3 inhibitor candidate, which is in development for the treatment of non-small cell lung cancer (NSCLC), melanoma, head and neck squamous cell carcinoma (HNSCC), and decompensated cirrhosis.
Galecto Inc Info
Ticker SymbolGLTO
Company nameGalecto Inc
IPO dateOct 29, 2020
CEOSchambye (Hans T)
Number of employees5
Security typeOrdinary Share
Fiscal year-endOct 29
Address75 State Street
CityBOSTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02109
Phone14570705210
Websitehttps://galecto.com/
Ticker SymbolGLTO
IPO dateOct 29, 2020
CEOSchambye (Hans T)
Company Executives of Galecto Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Julianne Bruno
Ms. Julianne Bruno
Independent Director
Independent Director
137.03K
--
Mr. Garrett Winslow
Mr. Garrett Winslow
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
1.85K
--
Ms. Lori Firmani
Ms. Lori Firmani
Interim Chief Financial Officer
Interim Chief Financial Officer
931.00
--
Dr. Jayson D.A. Dallas, M.D.
Dr. Jayson D.A. Dallas, M.D.
Independent Director
Independent Director
--
--
Dr. Carl M. Goldfischer, M.D.
Dr. Carl M. Goldfischer, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Hans T. Schambye, M.D., Ph.D.
Dr. Hans T. Schambye, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Amit D. Munshi
Mr. Amit D. Munshi
Independent Director
Independent Director
--
-100.00%
Mr. Matthew (Matt) Kronmiller
Mr. Matthew (Matt) Kronmiller
Executive Vice President of Strategy, Chief Business Officer
Executive Vice President of Strategy, Chief Business Officer
--
--
Mr. Peter Harwin
Mr. Peter Harwin
Independent Director
Independent Director
--
--
Dr. Chris W. Cain, Ph.D.
Dr. Chris W. Cain, Ph.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Julianne Bruno
Ms. Julianne Bruno
Independent Director
Independent Director
137.03K
--
Mr. Garrett Winslow
Mr. Garrett Winslow
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
1.85K
--
Ms. Lori Firmani
Ms. Lori Firmani
Interim Chief Financial Officer
Interim Chief Financial Officer
931.00
--
Dr. Jayson D.A. Dallas, M.D.
Dr. Jayson D.A. Dallas, M.D.
Independent Director
Independent Director
--
--
Dr. Carl M. Goldfischer, M.D.
Dr. Carl M. Goldfischer, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Hans T. Schambye, M.D., Ph.D.
Dr. Hans T. Schambye, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
FAQs
Who are the top five shareholders of Galecto Inc?
The top five shareholders of Galecto Inc are: Ms. Julianne Bruno
How many institutions hold shares of Galecto Inc (GLTO)?
As of 2026Q1, 56 institutions hold shares of Galecto Inc, with a combined market value of approximately 5.06M, accounting for 8.38% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 4120559.00.